Copy and pasted from Yahoo Finance. Interesting. MedMira will provide a regulatory and corporate update on the 22nd of December 2021, in the event of any material
changes, these will be provided before that date. In addition, the Company further enhanced its technology by developing a new production process for its colloidal gold immuno-conjugates. This will be launched in the coming months and further enhances the ease-of-use and with it provides additional benefits to the end-users. Subsequent to the financial year end 2021, MedMira has successfully completed its latest FDA inspection of the Company’s biological medical device products.In addition, the Company announces that it has completed the MDSAP audit and shall receive the MDSAP certification in early December 2021. Furthermore, the Company received the registered trademark for its REVEALCOVID-19®. The Company’s Finance team continued its fiscal constraints to maintain its low fixed costs with the aim to achieve breakeven and subsequent profitability within a short period of time. During FY2021, the Company continued its efforts to renegotiate its debt and achieved a forbearance agreement with MedMira’s largest debt holder which allows the Company to defer principal and interest payments for 12 months. This may be extended further depending on the growth of the Company. Subsequent to the financial year end 2021, MedMira entered into a financial package agreement pending on regulatory approval which will provide the Company with additional cash to execute its clinical trials (G4 HIV CLIA-waived Rapid Test), to continue its operations and to further invest into the manufacturing facility in Halifax. As an additional part of this agreement, MedMira and its stakeholders will benefit from a significant debt reduction to further support the Company’s going concern.